
Eric Raible
Managing Editor at Bryn Mawr Communications
Articles
-
1 month ago |
practicaldermatology.com | Eric Raible
Dermatologists gathered for the Acne and Rosea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD, respectively. Here’s what’s new in understanding, treating, and managing these conditions.
-
1 month ago |
practicaldermatology.com | Eric Raible
At the 2025 American Academy of Dermatology Annual Meeting, Dr. Bruce E. Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University School of Medicine, delivered a compelling presentation outlining transformative advancements in psoriasis treatment. These developments promise to improve patient outcomes and revolutionize clinical approaches.
-
2 months ago |
reachmd.com | Eric Raible
At one time dismissed or misunderstood, chronic itch has emerged in recent years as a significant focus in dermatology, thanks to advancements in research and treatment. "Itch is finally going mainstream," said dermatologist Dr. Shawn Kwatra (pictured), the Joseph W. Burnett Endowed Professor and Chairman of the department of dermatology at the University of Maryland, in his talk.
-
Jan 24, 2024 |
practicaldermatology.com | Eric Raible
Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
-
Jan 23, 2024 |
practicaldermatology.com | Eric Raible
A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clinical response at 48 weeks. “Hidradenitis suppurativa is a chronic and painful inflammatory skin disease associated with significant comorbidities and poor quality of life," the researchers wrote in the study abstract.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →